This New LY294002 Is Twice The Enjoyable

Conclusion:? In summary, our data support the safety and efficacy of CNI to MMF monotherapy conversion. ""Chan TSY, Hwang Y-Y, Gill H, Au W-Y, Leung AYH, Tse E, Chim C-S, Loong F, Kwong Y-L. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Abstract:? Nineteen consecutive patients with post-transplant lymphoproliferative disorders (PTLD) in an Asian population were reviewed. The histopathologic diagnoses http://www.selleckchem.com/products/jq1.html were monomorphic (CD20-positive diffuse large B-cell lymphoma, n?=?14); plasmacytic (n?=?1); Burkitt-like (n?=?1); natural killer cell lymphoma (n?=?1); lymphomatoid papulosis (n?=?1); and classical Hodgkin lymphoma (n?=?1). Early-onset ( was achieved in 17/19 (90%) of cases. Lactate dehydrogenase level, stage, extranodal involvement, EBV status, and International Prognostic Index had no impact on treatment outcome. EBV-positive PTLD occurred much later in Asian patients. Treatment results of PTLD were favorable. ""Shen J, Gill J, Shangguan M, Sampaio MS., Bunnapradist S. Outcomes of renal transplantation in recipients with Wegener��s granulomatosis. Clin Transplant 2011: 25: 380�C387. ? 2010 John Wiley & Sons A/S. Abstract:? Wegener��s granulomatosis (WG) is the leading cause of rapidly progressive glomerulonephritis-induced end-stage renal disease (ESRD). In this study, we compared transplant outcomes between recipients with ESRD caused by WG to recipients with ESRD secondary to other causes. Using OPTN/UNOS data from 1996 to 2007, 919 recipients with WG were identified. Post-transplant outcomes included rates of delayed graft function, acute rejection within one-yr post-transplant, overall and death-censored graft survival, and patient survival and were compared between recipients with ESRD secondary to WG versus ESRD from other causes. Recipients with ESRD because of WG had superior unadjusted and adjusted rates of graft loss, patient death, and functional graft loss (adjusted hazard ratio [HR] 0.711, 0.631, and 0.625 respectively, p?